Download PDF
Thorac Cardiovasc Surg 2007; 55(5): 317-321
DOI: 10.1055/s-2006-955961
Original Thoracic

© Georg Thieme Verlag KG Stuttgart · New York

A Prospective Phase II Study of a New Treatment Protocol for NSCLC Combined with Preoperative Mediastinoscopy and Chemotherapy

T. Nakajima1 , H. Kimura2 , M. Suzuki1 , H. Wada2 , S. Ando2 , T. lida2 , Y. Sekine1 , T. Fujisawa1
  • 1Department of Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
  • 2Division of Thoracic Diseases, Chiba Cancer Center, Chiba, Japan
Further Information

Publication History

received Sept 12, 2006

Publication Date:
16 July 2007 (online)

    Permissions and Reprints All articles of this category

Abstract

Background: We have developed a new multimodal treatment protocol combined with video-assisted mediastinoscopy (VAM) and chemotherapy. Methods: Forty-four pN2 non-small cell lung cancer (NSCLC) cases were selected from the surgically treated groups and the prognoses were compared between October 1998 and December 2004. Patients negative for nodes on examination by VAM (VAM-negative: group 2) underwent thoracotomy, and those positive for nodes (VAM-positive) received induction chemotherapy. After chemotherapy, only patients who met the surgical criteria underwent thoracotomy (group 3), and the remaining cases were allocated to radiotherapy (group 4) or best supportive care. When none of the VAM criteria were met (group 1), thoracotomy was performed without VAM. Results: The overall 3- and 5-year survival rates were 42.1 % and 28.0 %. The survival rates in groups 2 and 3 were almost the same (p = 0.5392), even though there were significantly more patients with multiple N2 stations in group 3 (p = 0.0088). Conclusions: Preoperative detection of lymph node metastasis by VAM makes use of the benefits of surgical intervention, and adjuvant therapies improve the survival of NSCLC patients with N2 disease.

Key words

cardiovascular surgery - heart and lung transplantation - thoracic surgery

References

  • 1 American College of Chest Physicians . Diagnosis and management of lung cancer: ACCP evidence-based guidelines. American College of Chest Physicians.  Chest. 2003;  123 (Suppl 1) S1-S337
    CrossrefPubMedGoogle Scholar
  • 2 Friedel G, Steger V, Kyriss T. et al . Prognosis in N2 NSCLC.  Lung Cancer. 2004;  45 (Suppl 2) S45-S53
    PubMedGoogle Scholar
  • 3 Robinson L A, Wagner Jr H, Ruckdeschel J C. American College of Chest Physicians . Treatment of stage IIIA non-small cell lung cancer.  Chest. 2003;  123 (Suppl 1) S202-S220
    CrossrefPubMedGoogle Scholar
  • 4 Riquet M, Assouad J, Bagan P. et al . Skip mediastinal lymph node metastasis and lung cancer: a particular N2 subgroup with a better prognosis.  Ann Thorac Surg. 2005;  79 225-233
    CrossrefPubMedGoogle Scholar
  • 5 Andre F, Grunenwald D, Pignon J P. et al . Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications.  J Clin Oncol. 2000;  18 2981-2989
    CrossrefPubMedGoogle Scholar
  • 6 Inoue M, Sawabata N, Takeda S. et al . Results of surgical intervention for p-stage IIIA (N2) non-small cell lung cancer: acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper lobe.  J Thorac Cardiovasc Surg. 2004;  127 1100-1106
    CrossrefPubMedGoogle Scholar
  • 7 Kimura H, Iwai N, Ando S. et al . A prospective study of indications for mediastinoscopy in lung cancer with CT findings, tumor size and tumor markers.  Ann Thorac Surg. 2003;  75 1734-1739
    CrossrefPubMedGoogle Scholar
  • 8 Ando S, Kimura H, Iwai N. et al . The significance of tumor markers as an indication for mediastinoscopy in non-small cell lung cancer.  Respirology. 2003;  8 163-167
    CrossrefPubMedGoogle Scholar
  • 9 Kimura H, Dobrenkov K, Iida T. et al . Tumor-draining lymph nodes of primary lung cancer patients: a potent source of tumor-specific killer cells and dendritic cells.  Anticancer Res. 2005;  25 85-94
    PubMedGoogle Scholar
  • 10 Kimura H, Yamaguchi Y. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma.  Cancer. 1997;  80 42-49
    CrossrefPubMedGoogle Scholar
  • 11 Kimura H, Yamaguchi Y. Adjuvant chemo-immunotherapy after curative resection of stage II and IIIA primary lung cancer.  Lung Cancer. 1996;  14 301-314
    CrossrefPubMedGoogle Scholar
  • 12 Giannitto G C, Giuffrida D, Pappalardo A. et al . Paclitaxel, carboplatin and gemcitabine combination as induction chemotherapy for stage IIIA N2 bulky non-small cell lung cancer.  Oncology. 2005;  69 295-300
    CrossrefPubMedGoogle Scholar
  • 13 Berghmans T, Paesmans M, Meert A P. et al . Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature.  Lung Cancer. 2005;  49 13-23
    CrossrefPubMedGoogle Scholar
  • 14 De Marinis F, Gebbia V, De Petris L. Neoadjuvant chemotherapy for stage IIIA‐N2 non-small cell lung cancer.  Ann Oncol. 2005;  16 (Suppl 4) iv116-iv122
    CrossrefPubMedGoogle Scholar
  • 15 Choi Y S, Shim Y M, Kim J. et al . Recurrence-free survival and prognostic factors in resected pN2 non-small cell lung cancer.  Eur J Cardiothorac Surg. 2002;  22 695-700
    CrossrefPubMedGoogle Scholar
  • 16 Ichinose Y, Kato H, Koike T. et al . Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station.  J Thorac Cardiovasc Surg. 2001;  122 803-808
    CrossrefPubMedGoogle Scholar
  • 17 Vansteenkiste J F, De Leyn P R, Deneffe G J. et al . Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases.  Ann Thorac Surg. 1997;  63 1441-1450
    CrossrefPubMedGoogle Scholar
  • 18 Tanaka F, Yanagihara K, Otake Y. et al . Prognostic factors in resected pathologic (p-) stage IIIA‐N2 non-small-cell lung cancer.  Ann Surg Oncol. 2004;  11 612-618
    CrossrefPubMedGoogle Scholar
  • 19 Mouroux J, Venissac N, Alifano M. Combined video-assisted mediastinoscopy and video-assisted thoracoscopy in the management of lung cancer.  Ann Thorac Surg. 2001;  72 1698-1704
    CrossrefPubMedGoogle Scholar
  • 20 Gephardt G N, Rice T W. Utility of frozen-section evaluation of lymph nodes in the staging of bronchogenic carcinoma at mediastinoscopy and thoracotomy.  J Thorac Cardiovasc Surg. 1990;  100 853-859
    PubMedGoogle Scholar
  • 21 Rooker S, Van Schil P, Van den Brande F. et al . Current outcome in patients with lung cancer and positive mediastinoscopy.  Acta Chir Belg. 2001;  101 273-276
    PubMedGoogle Scholar
  • 22 De Leyn P, Vansteenkiste J, Deneffe G. et al . Result of induction chemotherapy followed by surgery in patients with stage IIIA N2 NSCLC: importance of pre-treatment mediastinoscopy.  Eur J Cardiothorac Surg. 1999;  15 608-614
    CrossrefPubMedGoogle Scholar
  • 23 Vilmann P, Krasnik M, Larsen S S. et al . Transesophageal endoscopic ultrasound-guided fine-needle aspiration (EUS‐FNA) and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) biopsy: a combined approach in the evaluation of mediastinal lesions.  Endoscopy. 2005;  37 833-839
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Herth F J, Lunn W, Eberhardt R. et al . Transbronchial versus transesophageal ultrasound-guided aspiration of enlarged mediastinal lymph nodes.  Am J Respir Crit Care Med. 2005;  171 1164-1167
    CrossrefPubMedGoogle Scholar
  • 25 Yasufuku K, Chiyo M, Koh E. et al . Endobronchial ultrasound guided transbronchial needle aspiration for staging of lung cancer.  Lung Cancer. 2005;  50 347-354
    CrossrefPubMedGoogle Scholar
  • 26 Yasufuku K, Nakajima T, Motoori K. et al . Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer.  Chest. 2006;  130 710-718
    CrossrefPubMedGoogle Scholar

MD, PhD Hideki Kimura

Division of Thoracic Diseases
Chiba Cancer Center

666-2, Nitona-cho, Chuoh-ku

Chiba 260-8717

Japan

Phone: + 81 4 32 64 54 31

Fax: + 81 4 32 65 95 15

Email: lung@chiba-cc.jp